Clinical Trial Update: HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HAIC combined with cadonilimab and bevacizumab as first-line therapy for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cadonilimab
• HAIC (hepatic artery infusion chemotherapy)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Unrescetable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN